TABLE 2.

Individual description of patients treated by atezolizumab/bevacizumab.

Patient	Age (years)	Gender	Fibrosis	Etiology	AFP/CA19‐9 level a	Metastases	Size of biggest nodule (mm	Multiple nodules	Macro‐vascular invasion	Previous systemic treatment	Radiological response	Time under A/B (months)	Length of follow‐up (months)	Alive/dead at last news
First line
1	77	M	F0	NASH	175/0.03	Yes	19	Yes	No	No	Progression	3.2	4.0	Dead
2	26	M	F3	HBV	376/NA	Yes	210	No	Yes	No	Progression	2.5	12.6	Dead
3	63	M	F4	NASH + OH	94/NA	No	57	Yes	Yes	No	Partial response	6.4	14	Dead
4	32	M	F4	HBV	0.3/0.02	No	50	Yes	No	No	Stable disease	15.6	17	Alive
5	41	M	F2	HBV	1.85/NA	Yes	48	Yes	Yes	No	Progression	2.3	6	Dead
6	18	M	F0	HBV	1/3	Yes	80	Yes	No	No	Progression	2.2	6	Alive
7	75	M	F4	NASH	3.9/NA	Yes	NA	NA	No	No	Partial response	22.8	22.8	Alive
8	63	F	F4	NASH + OH	7142/11	Yes	160	Yes	Yes	No	NA	1	1.3	Dead
9	57	M	F3	HCV	1/NA	No	22	Yes	No	No	Partial response	16.1	16.1	Alive
Second line
10	79	F	F1	HCV	1.8/0.3	No	21	Yes	No	Gemcitabine + Oxaliplatin	Stable disease	4	20	Dead
11	67	F	F4	HBV	0.7/NA	Yes	60	Yes	No	Sorafenib	Stable disease	9	11	Dead
12	47	F	F4	HBV	25/1.5	Yes	118	Yes	No	Sorafenib	Stable disease	7	31	Dead
13	66	M	F4	NASH + OH	383/3.5	No	80	Yes	No	Gemcitabine + cisplatin	Partial response	24	24	Alive
14	79	M	F0	NASH + OH	378/NA	Yes	151	Yes	No	Gemcitabine + oxaliplatin	Stable disease	13.5	22	Dead
Third line
15	66	M	F4	HCV	714/3	No	131	No	Yes	Gemcitabine + cisplatin > 5FU + oxaliplatin	Progression	2	3.9	Dead
Fifth line
16	44	M	F4	HCV + OH	8642/2	Yes	12	No	No	Sorafenib > Gemcitabine + oxaliplatin >5FU + irinotecan > paclitaxel	Partial response	15.5	37	Alive

Abbreviations: A/B, atezolizumab/bevacizumab; F, female; HBV, hepatitis B virus; HCV, hepatitis C virus; M, male; NA, not available; NASH, non‐alcoholic steatohepatitis; OH, alcohol related liver disease.

^a Time fold of the upper limit of the normal.